X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.
Lead Product(s): Gepotidacin
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK 2140944
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
US FDA has accepted for review a Biologics License Application for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate. PDUFA action date for a regulatory decision by the US FDA on this application is 14 February 2025.
Lead Product(s): MenABCWY
Therapeutic Area: Infections and Infectious Diseases Product Name: MenABCWY
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.
Lead Product(s): GSK4382276A
Therapeutic Area: Infections and Infectious Diseases Product Name: Flu mRNA
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: CureVac
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2024
Details:
Blenrep (belantamab mafodotin-blmf) is a humanized anti-BCMA antibody/drug conjugate. It is being evaluated in phase 3 clinical trials in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Cabenuva is a combination of cabotegravir which inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for HIV replication and rilpivirine which inhibits HIV-1 reverse transcriptase.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Product Name: Cabenuva
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Apretude
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
GSK 2140944 (gepotidacin) is an investigational bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a novel mechanism of action. It is being evaluated for the treatment of uncomplicated urogenital gonorrhoea.
Lead Product(s): Gepotidacin
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK 2140944
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
S4V (shigella4V) is a tetravalent bioconjugate vaccine candidate, which is currently being evaluated for the treatment shigellosis-an infectious disease.
Lead Product(s): S4V
Therapeutic Area: Infections and Infectious Diseases Product Name: Shigella4V
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: LimmaTech Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin monoclonal antibody, which is being evaluated in the treatment of asthma, chronic rhinosinusitis with nasal polyps, nasal polyps.
Lead Product(s): AIO-001
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AIO-001
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Aiolos Bio
Deal Size: $1,400.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition February 15, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
